Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Milton S. Hershey Medical Center
National Cancer Institute (NCI)
Children's National Research Institute
Children's National Research Institute
Taproot Health
National Cancer Institute (NCI)
Emory University
National Cancer Institute (NCI)
Washington University School of Medicine
Children's Oncology Group
Eastern Cooperative Oncology Group
Florida International University
MacroGenics
Emory University
Celgene
Emory University
M.D. Anderson Cancer Center
Nationwide Children's Hospital
Masonic Cancer Center, University of Minnesota
Wake Forest University Health Sciences
Dana-Farber Cancer Institute
Novartis
SillaJen, Inc.
Memorial Sloan Kettering Cancer Center
Rutgers, The State University of New Jersey
City of Hope Medical Center
Valerio Therapeutics
Valerio Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
INSYS Therapeutics Inc
Children's Oncology Group
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center